Al-Tukmagi HF, Rasheed FA, Hussain SA., Adjuvant Use of Angiotensin Receptor Blockers with Metformin in Patients with Polycystic Ovary Syndrome. Pharmacologia. 2012;3(1):15-19.
Abstract
Background: PPARγ agonists are used in type 2 diabetic patients to reduce insulin resistance. Recently, many AT1 receptor antagonists (ARBs) were reported to function as partial agonists of PPARγ based on in vitro experiments. The aim of the present study was to investigate the effects of adjuvant use of ARBs (losartan, telmisartan or valsartan) with metformin on metabolic and hormonal status in women with polycystic ovary syndrome (PCOS). Methods: Using a single-blinded clinical trial, we compared the effects of losartan, telmisartan or valsartan, when adjunctly used with metformin, on insulin sensitivity, body mass index, glycemic control, and the serum levels of various hormones (FSH, LH and testosterone). In total, 74 Iraqi females with PCOS were enrolled in the study and allocated into 4 treatment groups; metformin only (1000 mg day-1) and metformin with losartan (25 mg), telmisartan (40 mg) or valsartan (40 mg). Results: All ARBs significantly reduced BMI, FBG and C-peptide values compared to the metformin-only-treated group; they also showed significantly greater effects in increasing plasma levels of FSH and decreasing both LH and testosterone levels compared to metformin-only treatment. The rank for the effects of the used ARBs in this respect was: telmisartan>losartan>valsartan after 4 months of treatment. Conclusion: Adjuvant use of ARBs with metformin improves their effect in the treatment of women with PCOS, with the most pronounced effect for telmisartan in this respect.
https://scialert.net/abstract/?doi=pharmacologia.2012.15.19
Customer Reviews
Thanks for submitting your comment!